article thumbnail

Leading API chemical companies in contract marketing

Pharmaceutical Technology

Various factors have contributed to the need and growth of API chemical suppliers such as rising healthcare expenditure, increasing disposable incomes, growing geriatric population, increasing incidence of chronic diseases, patent expiration of blockbuster drugs, increased consumption of generic drugs, and intervention of the new generation APIs.

Marketing 130
article thumbnail

Leading retail pharmacies in pharma

Pharmaceutical Technology

The list includes companies offering various products and services, including but not limited to: ยท Over-the-counter drugs. Prescription refill and generic drug programmes. The document contains detailed information on the suppliers and their product offerings, alongside contact details to aid your purchasing or hiring decision.

Pharmacy 147
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

FDA Approves First Generic of Symbicort to Treat Asthma and COPD

The Pharma Data

Agency Supports Development of Complex Generic Drug-Device Combination Product to Improve Competition and Access to More Affordable Medicines. This complex generic drug-device combination product, which is a metered-dose inhaler, should not be used to treat acute asthma attacks. Today, the U.S.

article thumbnail

OPQโ€™s 2023 Annual Report: an Upbeat Review of CDERโ€™s Quality Efforts

FDA Law Blog

This yearโ€™s report noted that CDERโ€™s Drug Product Catalog contains over 140,000 entries, the same amount as OPQ listed in 2022. In a display of the competition within the generic industry that keeps margins low , this total included 118 new drug applications and 956 generic drug applications.

article thumbnail

In the News: September 2021 Regulatory and Development Updates

Camargo

The Center for Drug Evaluation and Research (CDER) has announced the rollout of the Novel Excipient Review Pilot Program in Federal Register Vol. The pilot program is the first step in allowing manufacturers to receive a preliminary review of a novel excipient, prior to drug product formulation. Container-closure changes.

article thumbnail

FDA Knows Its Own Strengthโ€”and It Includes Concentration

FDA Law Blog

Relevant here, FDA interpreted in Guidance that a proposed injectable biosimilar must โ€œdemonstrate that its product has the same strength as the reference product by demonstrating that both products have the same total content of drug substance (in mass or units of activity) and the same concentration of drug substance.โ€

article thumbnail

In the News: October Regulatory and Development Updates

Camargo

When the FDA requires a productโ€™s labeling to include a boxed warning (also called a โ€œblack box warningโ€ because the text is surrounded by black border), the potential market value of the drug often drops severely. Presumably, Antaresโ€™ long-established 90-person urology sales force can achieve pull-thru of this drug product.